Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article by Health referenced a June 2019 contributor piece published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The contributor article, titled “The Deadly Costs of Insulin,” noted the significant price increases of insulin treatment, from $14 for 1 vial in 2001 to $275 in 2019.
A piece by Patheos spotlighted an article published on AJMC.com, titled “Mental Health Issues On the Rise Among Adolescents, Young Adults.” The article details rates of mood disorders and suicide-related outcomes that have increased significantly among adolescents and young adults, with a possible link to the rise of social media.
An article by Herald-Tribune cited a study published in the January 2021 issue of AJMC® titled “Differences in the Use of Telephone and Video Telemedicine Visits During the COVID-19 Pandemic.” The study found lower use of video vs telephone visits among older, Black, Hispanic, and Spanish-speaking patients amid the COVID-19 pandemic, driven largely by clinician and practice factors.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen